We have a broad portfolio covering a wide range of therapeutic areas, and across modalities, from small molecules to cell therapy. Many have already attracted investments from top-tier investors such as Pureos Bioventures, NEA, Orbimed, Syncona, Sofinnova, the Novartis Venture Fund, Biomedinvest, Boehringer Ingelheim Venture Fund, Kurma Partners, Sunstone Life Science Ventures, Ysios Capital, Morningside Venture Investments, Jeito Capital, Versant Ventures, Novo Holdings, RA Capital Management and others.
Financed: $50M raisedÂ
Combining cell-shielding and immunotherapies to safely treat hematologic disorders, targeting diseased cells while preserving healthy ones and resisting immunotherapy depletion
Financed: $366M raised
Anti-Claudin-1 antibody-drug conjugates and monoclonal antibodies to treat cancer and reverse fibrosis
Financed: $155M raised
Cytokine based cancer therapies harnessing the power of the immune system

Incubating
A novel class of oral immunosuppressive therapies for chronic T cell-mediated autoimmune diseases

Incubating
Cyclic short peptides platform for the selective capturing of metal ions in metal-related pathologies

Financed: $41.5M raised
Stopped
Glycomimetic platform for removing auto-antibodies in autoimmune neuropathies

Stopped
First-in-class therapeutics to stop neurodegenerative diseases with a selective small molecule approach
Financed: $16M raised
Highly potent, targeted soluble T cell receptor therapies for solid tumors, using AI-guided engineering to enhance affinity, stability, and safety

Incubating
RNA-based therapeutics targeting mitochondrial function and ER stress for liver disease treatment

Stopped
Developing novel inflammasome inhibitors
Financed: $25M raised
First-in-class endocannabinoid modulators to restore brain function in CNS disorders, targeting stress, anxiety, and related conditions